Skip to main content

Jalyn FDA Approval History

FDA Approved: Yes (First approved June 14, 2010)
Brand name: Jalyn
Generic name: dutasteride and tamsulosin
Dosage form: Capsules
Company: GlaxoSmithKline
Treatment for: Benign Prostatic Hyperplasia

Jalyn is a combination of dutasteride (5α-reductase inhibitor) and tamsulosin (alpha-adrenergic antagonist) indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

Development timeline for Jalyn

Jun 14, 2010Approval FDA approves Jalyn, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.